Mezzion Pharma has filed a suit against Dr Reddy’s Laboratories in the US
Mezzion has filed a suit for damages against Dr. Reddy’s in New Jersey State Court alleging that Dr. Reddy’s committed fraud relating to the latter hiding significant deficiencies in its Food and Drug Administration (FDA) cGMP practices, and misrepresenting its compliance to Mezzion. According to Dr. Reddy’s, they have not been served with any legal papers or legal process in the matter referred to in Mezzion’s press release. In 2015, Dr. Reddy’s had received a warning letter from the US Food and Drug Administration (USFDA) for two of its active pharma ingredients (API) manufacturing plants and a formulation facility located in Andhra Pradesh and Telangana.
Sanofi’s antibody to treat patients with rheumatoid arthritis gets Approved
Sanofi has received approval from Health Canada for Kevzara (sarilumab), an interleukin-6 (IL-6) receptor antibody, to treat adult patients with moderately to severely active rheumatoid arthritis (RA). The approval was based on data from about 2,900 adults with moderately to severely active RA who had an inadequate response to previous treatment regimens. The fully human monoclonal antibody Kevzara binds specifically to soluble and membrane-bound IL-6 receptors, and has been shown to inhibit IL-6-mediated signalling through these receptors.
